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Highlights 31 
 Sensory axons are often more affected than motor in disease. However, the size and 32 
latency of the corresponding action potential hampers studies of their properties using 33 
threshold tracking. 34 
 This paper addresses these difficulties, with techniques and an amplifier of simple 35 
construction. We demonstrate the tracking of 2-µV targets without excessive 36 
averaging, and thereby increase the applicability of excitability studies. 37 
 The ability to record sensory potentials in patients with a variety of neuropathic 38 
conditions may benefit from the ability to record potentials as small as those recorded 39 
here. 40 
 41 
Abbreviations 42 
CMAP, compound muscle action potential; CMR(R), common-mode rejection (ratio); CSAP, 43 
compound sensory action potential; CTS, carpal tunnel syndrome; EMG, electromyogram; 44 
IC, integrated circuit; IV, current-threshold relationship; NCS, nerve conduction study; QT, 45 
charge-duration; RC, recovery cycle; TE, threshold electrotonus; SNR, signal-to-noise ratio; 46 
SR, Stimulus-response. 47 
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Abstract 49 
Background: Excitability studies on normal and diseased human axons in vivo have been 50 
greatly enhanced by fast non-invasive threshold-tracking techniques, using surface 51 
stimulation and recording. Although sensory axons are often more affected in disease, most 52 
studies to date have focussed on motor axons, because of technical difficulties in resolving 53 
pathologically small nerve volleys in the presence of noise and stimulus artefact. 54 
New Methods:  This paper describes techniques for tracking low-amplitude compound 55 
action potentials, using a  battery-powered, isolated preamplifier of simple construction with 56 
high common mode rejection (>125 dB [balanced inputs]) and low noise (<0.4 µV referred to 57 
inputs [shorted]). 58 
Results: We demonstrate the preamplifier’s capability by tracking targets as small as 2 µV 59 
for a full range of excitability measurements without the usual distortion due to residual 60 
stimulus artefact and without the need for clamping, additional filtering or ensemble 61 
averaging. 62 
Comparison with existing methods: In practice, threshold-tracking studies have been 63 
unable to study sensory axons when the maximal compound sensory action potential was less 64 
than about 15 µV. The techniques and amplifier in the present study allow measurements to 65 
be made from nerve with maximal responses less than half that size, and we present three 66 
recordings in patients with pathologically small nerve action potentials ≤7µV. 67 
Conclusions: Based on measurements of stimulus artefact distortion, noise and the 68 
performance in experiments, we conclude that the techniques described here will facilitate the 69 
study of diseased axons for which the sensory potentials have high thresholds and may be 70 
only a few microvolts in amplitude. 71 
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1 Introduction 72 
Non-invasive threshold tracking techniques have been applied to the study of the underlying 73 
mechanisms of a wide range of neuropathologies (reviewed in: Krarup and Moldovan, 2009; 74 
Krishnan et al., 2009). As a rapid in vivo method, threshold tracking is able to examine the 75 
action of a variety of drugs and toxins in human and animal subjects in real time (Kiernan et 76 
al., 2005; Krishnan et al., 2005; Kuwabara and Misawa, 2008; Nodera and Rutkove, 2012; 77 
Park et al., 2009). 78 
In contrast to fixed stimulus studies, where the intensity of both conditioning and test stimuli 79 
are set and then kept constant, threshold tracking tests the effect of a conditioning stimulus by 80 
automatically adjusting the test stimulus intensity to maintain a response at a pre-determined 81 
fraction of the maximal compound action potential. This target response is commonly 40-82 
50% of maximum because this lies on the steepest part of the stimulus-response curve. 83 
Even in subjects with only a few surviving motor units, the size and latency of the compound 84 
muscle action potential (CMAP) may be sufficient to allow a clean and artefact-free 85 
recording. In the study by Kiernan and colleagues (2000) which introduced the technique for 86 
the rapid measurement of multiple measures of axonal excitability, and established normative 87 
data for clinical testing, the maximal CMAP of thenar muscles to the median nerve 88 
stimulation was, on average, 8.4 mV (baseline to peak) and, in a recent report of nerve 89 
conduction studies on a large cohort of healthy individuals, it was 9.1 mV with a latency of 90 
onset of ~3.6 ms (Benatar et al., 2009). 91 
In contrast excitability studies on sensory axons are technically more challenging, primarily 92 
because they depend on nerve action potentials which are much smaller and have shorter 93 
latencies (Krarup, 2004). The compound sensory action potential (CSAP) is measured in 94 
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microvolts and recorded antidromically from the surface with lower limits in relatively young 95 
subjects of 26 µV (Kiernan et al., 2001) and 18.1 µV (Howells et al., 2012), when measured 96 
peak to peak. However, in 100 normal subjects, Benatar and colleagues (2009) reported the 97 
maximal median sensory CSAPs of 3.1 to 86 µV, dependent on age, though the measurement 98 
was baseline to peak. In threshold tracking studies, the target potential is submaximal, 99 
typically 40 – 50% of the maximal CSAP, so that there may be an inadequate signal-to-noise 100 
ratio, in normal subjects, particularly the elderly. 101 
Currently there is no commercially available system for electromyography and nerve 102 
conduction studies (EMG/NCS) with a real time analogue output suitable for tracking the 103 
threshold of sensory axons. 104 
In order to track small CSAPs efficiently, the preamplifier requires low noise and high 105 
common mode rejection. In addition, for small CSAPs close to the noise level, the threshold 106 
tracking strategy needs to take account of the fact that a ‘response’ may be due to noise alone. 107 
This paper shows how a preamplifier of simple construction can be used to track microvolt 108 
potentials just above the noise floor established by the recording electrodes, without 109 
significant intrusion of the stimulus artefact into the recording. We show how it is possible to 110 
study selectively the most excitable sensory axons, well below previously recorded 111 
measurements. 112 
2 Methods 113 
To assess the feasibility of recording axonal excitability with small CSAPs, 14 experiments 114 
were performed on three healthy subjects and three subjects with neuropathies resulting in 115 
small CSAPs. Recordings of low amplitude targets (~4 µV) were performed on one subject 116 
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on five separate occasions. All studies were performed with the approval of The University of 117 
Sydney’s Human Research Ethics Committee, and in conformity with the Declaration of 118 
Helsinki.  119 
2.1 Preamplifier 120 
2.1.1 Design 121 
The preamplifier used in this study is illustrated in the Fig. 1 and broadly consists of an input 122 
and output stage galvanically separated by an isolation amplifier (ISO124, Burr Brown). The 123 
instrumentation amplifier IC (AD8221BR) has exceptional common mode rejection (CMR) 124 
and low noise characteristics and the inputs are protected against 1 kV human body model 125 
electrostatic discharge (AD8221 datasheet, Analog Devices). High-pass filtering of electrode 126 
offsets is achieved by bootstrapping the output by tying the instrumentation amplifier 127 
reference to the low-passed output, thereby preserving the high common mode rejection. 128 
Universal active filters (UAF42, Texas Instruments) are used to simplify the filter design; the 129 
first UAF is configured as a two-pole high-pass (0.2 Hz) Butterworth filter which also 130 
provides the low-pass reference signal for the instrumentation amplifier. The second UAF is a 131 
two-pole high-pass (2 Hz) Butterworth filter to remove motion artefact. The final pair of 132 
UAFs is configured as a four-pole low-pass (2 kHz) Bessel filter, which has superior step 133 
response characteristics and is positioned so as to additionally remove the ripple due to the 134 
modulation/demodulation carrier frequency of the isolation amplifier. The instrumentation 135 
amplifier is configured with a fixed gain of 250 which is suitable for amplification of CMAPs 136 
while still achieving good CMR for sensory potentials. Additional gain (x40) for CSAPs is 137 
achieved using the auxiliary amplifier of the second UAF. The input and output stages are 138 
each powered by a pair of 9-volt (PP3) batteries, and the integrated circuits (ICs) are placed 139 
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so that the current drain is balanced on either side of the isolation. The preamplifier was 140 
easily constructed on a single-sided circuit board (100x100 mm) with socketable ICs (apart 141 
from the surface mount instrumentation amplifier) and through-hole passive components. 142 
2.1.2 Bench tests 143 
The frequency response was tested by applying a 0.5-mV sinusoidal signal to the 144 
preamplifier’s inputs and measuring the peak response as a function of frequency between 0.2 145 
Hz and 10 kHz. 146 
The common mode rejection between 10 Hz and 10 kHz was determined by measuring the 147 
amplitude of a sinusoidal signal between the preamplifier’s inputs (differential-mode, Adiff) 148 
required to give the same output response as a large sinusoidal signal at both inputs 149 
(common-mode, Acm). The common mode rejection ratio (CMRR) is calculated as: CMRR = 150 
-20 * log10(Adiff/Acm). 151 
2.2 Electrodes and skin preparation 152 
Skin impedance was lowered at both the recording and stimulation sites by abrasion of the 153 
skin surface (3M Trace Prep, 3M, Ontario, Canada), followed by cleaning with an isopropyl 154 
alcohol swab. Sensory potentials were first recorded antidromically from digit 2 using 155 
disposable Ag/AgCl ring electrodes (RE-D, The Electrode Store, Enumclaw, WA, USA), 156 
with two ring electrodes 4 cm apart (Eduardo and Burke, 1988), with the more proximal 157 
electrode around the proximal phalanx. The cathode, anode and ground electrodes were of the 158 
disposable Ag/AgCl ECG type (1010M & 4620M, Unilect, Unomedical, Stonehouse, UK). 159 
The ground electrode was placed on the dorsal aspect of the hand. The cathode was located at 160 
the wrist crease with the anode 10 cm proximally, towards the radial edge of the forearm. The 161 
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location of the cathode was adjusted to obtain the minimum threshold current so reducing 162 
further the stimulus artefact. 163 
2.3 Excitability testing 164 
Axonal excitability was tested with the QtracS threshold tracking software (© Prof Hugh 165 
Bostock, Institute of Neurology, UCL, UK) using a stimulus-response paradigm which 166 
controlled both the stimulation and recording through a 16-bit multifunction data acquisition 167 
device (NI USB-6251). 168 
The stimuli were delivered by an isolated bipolar constant current stimulator (DS5, Digitimer, 169 
Welwyn Garden City, UK) which followed a real-time command voltage which was 170 
synchronised with the recording sweep. The compound action potentials were amplified by 171 
the preamplifier (gain x10k) and bandpass filtered (2 Hz to 2 kHz). The amplified waveform 172 
had any residual mains frequency noise removed with a HumBug 50/60 Hz noise eliminator 173 
(Quest Scientific, North Vancouver, BC, CA) before being digitised at a sampling frequency 174 
of 10 kHz. 175 
As described in previous studies (Bostock et al., 1998; Howells et al., 2012; Kiernan et al., 176 
2000; Kiernan et al., 2001; Tomlinson et al., 2010) the TROND protocol cycles through five 177 
measures of axonal excitability: stimulus-response (SR) curve, strength-duration relationship 178 
(plotted as charge-duration [QT]), threshold electrotonus (TE), current-threshold (IV) 179 
relationship and a recovery cycle (RC). 180 
2.4 Tracking small, noisy action potentials 181 
For most of the CSAPs recorded, the maximal CSAP and the signal to noise ratio (SNR) were 182 
sufficient to allow “proportional tracking” (as in the usual TROND protocol; Kiernan et al., 183 
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2000; Kiernan et al., 2001). Proportional tracking adjusts the stimulus step size in proportion 184 
to the error between the actual and target responses, allowing fast tracking when the stimulus 185 
conditions change rapidly and finer tracking control of the stimulus for slow events. For the 186 
smallest CSAPs and noisier recordings, a different tracking strategy was adopted, since the 187 
lower SNR meant that proportional tracking would have resulted in excessive oscillations 188 
about the target response. A more conservative approach was taken where the basic stimulus 189 
step size was a fixed percentage (Δ) of the current stimulus. If successive responses fell on 190 
the same side of the target then, the step size was increased by Δ, 2Δ, 3Δ and 4Δ% of the 191 
current stimulus until the target was met (and vice versa). On the other hand, when successive 192 
responses fell on opposite sides of the target, the step size was halved until it returned to the 193 
basic step size of Δ. This method is referred to as ‘arithmetic/geometric tracking’. 194 
For low SNR recordings the peak-to-peak measurement accuracy of the biphasic CSAPs was 195 
improved by requiring the positive peak to precede the negative peak (i.e. peak[+]-to-peak[-196 
]). 197 
2.5 Post digitisation signal conditioning 198 
Two passes of a 1-2-1 binomial smoothing filter (Marchand and Marmet, 1983) were applied 199 
to the digitised data in order to remove high-frequency noise acquired after amplification or 200 
as a result of the digitisation process. The transfer function for this low-pass Gaussian filter is 201 
ܪሺ݂ሻ ൌ cosସሺగଶ
௙
௙ಿሻ, where ே݂ is the Nyquist frequency. Initial observations of the digitised 202 
waveforms showed that the stimulus artefacts were small and the return to baseline was 203 
nearly complete before the onset of the CSAP. As such, previously required “clamping” 204 
techniques were unnecessary, and the measurement window could be shortened (see 205 
Discussion). 206 
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3 Results 207 
The circuit diagram of the amplifier is shown in Fig. 1A. 208 
3.1 Amplifier performance 209 
With the preamplifier’s inputs shorted and the gain set to x10k the output of the preamplifier 210 
was measured with a true RMS multimeter (34401A, Agilent) to be 3.85 mV, or 0.385 µV 211 
when referred to the amplifier’s inputs (RTI). There was no appreciable attenuation in the 212 
frequency response of the amplifier between 5 and 1000 Hz (Fig. 1B). Beyond 5 kHz the 213 
filter roll-off was 22.3 dB/octave. The high-pass filter has an attenuation of 11 dB/octave 214 
below 1 Hz but steepens to 14.9 dB below 0.5 Hz due to the ac-coupling arrangement. The 215 
equivalent ‘noise bandwidth’ was calculated from the frequency response (Fig. 1B) and was 216 
2.4 kHz which gives a noise density of 7.9 nV/√Hz (RTI), in close agreement with the figure 217 
in the manufacturer’s datasheet. 218 
With balanced inputs the common mode rejection was greater than 136 dB below 500 Hz and 219 
had a minimum value of 125 dB (Fig. 1C) over the bandwidth of the amplifier (2 kHz). 220 
3.2 Recovery from stimulus artefact during CSAP recruitment 221 
Figure 2 illustrates the recovery from stimulus artefact during the recruitment of sensory 222 
fibres by gradually increasing stimulus strengths. Subject #1 had higher recruitment 223 
thresholds (right column) and from the greater stimulus artefact and background noise, most 224 
probably a greater skin surface-electrode impedance. The peak deflections due to stimulus 225 
artefact were 8.5, 5.2 and 2.2 µV for Subjects #1, 2 and 3 respectively. In all three recordings 226 
the stimulus artefact had decayed to a negligible value before the CSAP onset. 227 
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3.3 Signal-to-noise measurements in vivo 228 
Two passes of the binomial smoothing filter resulted in an additional attenuation of high 229 
frequency noise (post-digitisation) with a steep roll off and a -3 dB point at 4.4 kHz (Fig. 1B, 230 
open circles). 231 
With the lowest amplitude targets, 10% of CSAP and 2 µV, a measure of the equivalent noise 232 
was obtained in one subject (Fig. 3) by sampling the waveform in a window of the same 233 
width, but prior to the stimulus (arbitrarily 50 ms earlier than the peak measurement). The 234 
noise measured this way was 0.8 ± 0.5 µV (mean ± SD; closed circles in Fig. 3), not 235 
surprisingly the same for both the 10% (~ 4 µV) and 2-µV targets. The standard deviations 236 
for the peak measurements were slightly higher (2 µV, 0.55 µV; 10%, 0.6 µV) reflecting the 237 
additional variation in amplitude in response to a tracking stimulus, which is, of necessity, 238 
not constant. The vertical bars in Fig. 3 show one standard deviation from the mean 239 
measurements. The 10% target and noise are separated by approximately three standard 240 
deviations from their means, while the 2-µV target and noise are separated by a little more 241 
than one standard deviation. 242 
The signal-to-noise ratio (SNR) was calculated from these data using the formula: 243 
ܴܵܰ ൌ ቀோெௌ೛೐ೌೖோெௌ೙೚೔ೞ೐ቁ
ଶgiving 19.2 and 5.0 for the 10% and 2-µV targets respectively. 244 
3.4 Threshold tracking small sensory action potentials 245 
3.4.1 Healthy subjects 246 
We found that the smallest practical limit of CSAP size that could be tracked without 247 
averaging was 2 µV (except for RC; see Legend to Fig. 4 and Discussion). Using 248 
‘arithmetic/geometric’ tracking of peak[+]-to-peak[-] amplitudes (see Methods), it was 249 
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possible to obtain all measures of axonal excitability for the 2-µV target in less than 32 min 250 
(Fig. 4 [Subject #3], see also Fig. 3B [Subject #2]). The measures from recordings in the 251 
three subjects are shown in Fig. 5 (filled circles), and compared with conventional recordings 252 
tracking responses 40-50% of maximal in the same subjects (open circles). 253 
These recordings suggest that the low-threshold afferents have a greater inward rectification 254 
much as in motor axons (Shibuta et al., 2010; Trevillion et al., 2010). However, unlike motor 255 
axons there is a suggestion of a relatively depolarized resting membrane potential in these 256 
low-threshold sensory axons. 257 
3.4.2 Neuropathy 258 
Threshold tracking recordings were made in three subjects with neuropathies that resulted in 259 
small CSAPs (Kennedy’s disease, amyloid neuropathy and chronic inflammatory 260 
demyelinating polyneuropathy [CIDP]) as shown in Fig. 6. The maximal CSAPs were: 261 
Kennedy’s disease, 5.2 µV; amyloid neuropathy, 6.5 µV; and CIDP, 7 µV, and the tracked 262 
target CSAPS were 2.1, 2.6, and 2.8 µV, respectively. Recordings of such low-amplitude 263 
sensory potentials were not previously possible without averaging many sweeps. 264 
3.5 Repeatability of low target recordings 265 
Recordings of the 10% target (4.1 ± 0.3 µV) were made in the same subject on five different 266 
occasions and are shown in Fig. 7. In the charge-duration plot (QT, Fig 7A) the slope of the 267 
lines represents rheobase, and not surprisingly it differs between the individual recordings 268 
with differing application of stimulating electrodes. The strength-duration time constant on 269 
the other hand was consistent between the recordings (721 ± 22 µs), but longer than the value 270 
reported by Kiernan and colleagues (2001) of 527 µs, which was obtained at a target level of 271 
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40%. Reproducibility of the other excitability recordings was very good, so that the 5 lines 272 
for the 5 different recordings can seldom be distinguished. 273 
Variability in the recovery cycle recordings is partly due to a reduction in the SNR inherent in 274 
the recording technique for the recovery cycle. The response to the supramaximal 275 
conditioning stimulus is first subtracted from the conditioned test response before the peak 276 
measurement is made, thereby increasing the noise contribution by √2, halving the SNR. 277 
4 Discussion 278 
This paper tackles the difficulty in obtaining reliable measures of the excitability properties 279 
of cutaneous sensory axons of low threshold. It is with diseased nerves with pathologically 280 
small CSAPs and high thresholds that the true usefulness of the techniques described here 281 
may be realised, and the described amplifier has now been used in hundreds of recordings 282 
and many of them involving pathologically small CSAPs. The discussion will focus on the 283 
optimal recording conditions for small CSAPs, the advantages of the amplifier design, and 284 
the physiological and clinical need for better recording techniques. 285 
4.1 Axonal excitability close to the electrode noise floor 286 
Synchronous mains frequency noise is to some extent always present in raw biosignals, 287 
particularly those acquired from the surface. Notch filters distort action potential 288 
measurements and in any case they do not remove the higher harmonics. In-line reduction of 289 
mains frequency noise can be achieved in hardware by a device such as the HumBug 290 
50/60Hz noise eliminator, or in software by sampling a stimulus free portion of the recording 291 
to remove a mains-locked waveform from the response. 292 
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Asynchronous noise due to the impedance of the electrode and skin-electrode interfaces or 293 
noise due to the amplification system itself all impact on the signal-to-noise ratio. The 294 
amplitude of both synchronous and asynchronous noise can be attenuated by careful skin 295 
surface preparation at the recording site and an amplifier with both high common mode 296 
rejection and low noise. 297 
Because the stimulus artefact tail frequently intrudes into the CSAP, so that it rides on the 298 
decaying artefact, the standard TROND protocol contains a correction for a sloping baseline 299 
in CSAPs by “clamping” the digitised data during the measurement window. The sloping 300 
baseline is removed by subtracting a straight line that passes through the start and finish of 301 
the measurement window at amplitudes corresponding to the mean of the ten samples 302 
recorded on either side of the measurement window. This type of clamping assumes that the 303 
artefact at the time of the response can be represented as a straight line, whereas it is usually 304 
more exponential than linear, so that clamping introduces a systematic and nonlinear 305 
distortion of the peak-to-peak measurement. In addition, movement of the CSAP within the 306 
measurement window due to changes in its latency alters the amount of distortion. The 307 
degree of nonlinearity of the stimulus artefact decay during the measurement window also 308 
determines the minimum observable action potential. 309 
Alternatives for removing the stimulus artefact after acquisition include artefact subtraction 310 
and localised fitting of the baseline; however for threshold tracking of small amplitude 311 
potentials these methods have their drawbacks. Artefact subtraction involves the delivery of a 312 
fractional stimulus which is subthreshold; the response is then scaled back up to achieve the 313 
stimulus artefact alone. Artefact subtraction can be an effective tool for reducing the stimulus 314 
artefact (Trevillion et al., 2010); however it doubles the recording time and halves the SNR. 315 
Further, because the artefact does not scale linearly with stimulus intensity, the artefact 316 
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removal is not complete. Another technique is to fit a curve to the decay of the stimulus 317 
artefact (Wagenaar and Potter, 2002). Axonal excitability studies, however, involve 318 
conditioning the test stimulus with sub- and supra-threshold pulses, in which the conditioning 319 
artefact or response may extend beyond the test stimulus. 320 
The arithmetic/geometric tracking applied to the 2-µV potentials in this study, was slower at 321 
tracking sharp transitions in stimulus conditions; on the other hand it was less susceptible to 322 
noise and overall it resulted in faster tracking of low signal-to-noise-ratio potentials. 323 
Recovery cycle measurements in sensory axons with low SNR were further improved with a 324 
hybrid recording protocol. For intervals shorter than 30 ms (which allows for possible M-325 
responses and F-waves), the response to the supramaximal conditioning stimulus needs to be 326 
subtracted from the conditioned test. To overcome the resultant halving of the SNR, 327 
ensemble averaging of 4 responses was performed for these intervals only (see RC2 in Fig. 328 
4). 329 
4.2 Conclusion 330 
Unlike nerve conduction studies which study the conduction of action potentials along a 331 
segment of nerve, threshold tracking studies probe the excitability under the stimulating 332 
cathode. The ability to track CSAPs as small as 2 µV opens up the possibility of documenting 333 
the properties of nerves and nerve branches not commonly studied, in addition to allowing 334 
studies documenting the progression and response to treatment of patients with sensory 335 
involvement in polyneuropathies such as kidney disease, (Krishnan et al., 2006), diabetes 336 
(Krishnan et al., 2008) and chemotherapy (Park et al., 2011). It is likely that the amplifier will 337 
be important in clinical trials. 338 
Disclosures 339 
16 
 
H.B. receives a share of the royalties for the sales of the Qtrac software. 340 
Acknowledgments 341 
This research was supported by ForeFront, a collaborative research group supported by the 342 
National Health and Medical Research Council of Australia (Program Grant #1037746). J.H. 343 
was supported by the Dawn Wallace MND fellowship from the Brain Foundation of 344 
Australia. S.B.P was supported by a Career Development Fellowship from the National 345 
Health and Medical Research Council of Australia. 346 
  347 
17 
 
 348 
 349 
  
Figure 1. Battery-powered isolated preamplifier for small sensory potentials. 350 
A. Circuit schematic. The circuit is powered by two pairs of 9-volt batteries and the subject 351 
is galvanically isolated from the data acquisition system by the isolation amplifier (ISO124P). 352 
The subject ground is tied to the midpoint (GND1) of the pair of batteries on the subject’s 353 
side of the isolation amplifier, whereas the amplifier’s output is referenced to the midpoint 354 
(GND2) of the pair of batteries on the data acquisition side of the isolation amplifier. The 355 
instrumentation amplifier (AD8221BRZ) provides the critical first stage of amplification and 356 
is set to a gain of x250 with a 1% 200Ω resistor (matched as close as possible to 198.4Ω). 357 
The first active filter chip decouples any dc-offset potentials. The second active filter is a 2-358 
pole Butterworth high-pass filter (fc=2Hz) for the removal of motion artefact. The 3rd and 4th 359 
active filter chips combined provide a 4-pole low-pass Bessel filter (fc=2 kHz) to limit the 360 
measurement bandwidth. B. Normalised frequency response measured with a 0.5-mV sine 361 
wave. The gain is normalised to the maximal bandpass response. The dotted lines indicate the 362 
band-pass (2 Hz to 2 kHz). The open circles indicate the low-pass filter characteristics of two 363 
applications of a 1-2-1 Gaussian filter for data sampled at 10 kHz. C. Common mode 364 
rejection vs. frequency. The dotted line corresponds to the -3dB frequency of the low pass 365 
filter, and shows a minimal CMRR of 125 dB over the amplifier’s bandwidth. 366 
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 367 
Figure 2: Recovery from stimulus artefact during CSAP recruitment. Left column. 368 
Averaged CSAP response waveforms to six consecutive stimuli (0.5-ms wide) of 369 
progressively increasing intensity for three subjects. Right column. Peak-to-peak 370 
measurements for each of the waveforms in the left column. The arrows indicate the 2-µV 371 
target for each subject.  372 
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 373 
Figure 3: Signal-to-noise ratio (Subject #2 in Fig. 2). The data represents the peak-to-peak 374 
amplitudes of the control channel (unconditioned test; open circles) and the equivalent noise 375 
(closed circles). The equivalent noise was measured in an earlier window which preceded the 376 
test stimulus. The solid lines indicate the mean amplitude and the dashed lines the mean 377 
noise. The vertical bars indicate one standard deviation from the mean. A. 10% target (~4 378 
µV) of maximal CSAP. B. Target 2 µV. Note that some of the variability in the test data 379 
(open circles) is because the stimulus was changing to track the threshold for the target 380 
CSAP. 381 
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 385 
 386 
Figure 4:  Threshold tracking a 2 µV target potential (Subject #3). The various components 387 
of the recording are marked below the data in A: SD, strength-duration relationship; TE, 388 
threshold electrotonus; IV, current-threshold relationship; RC1, recovery cycle part 1 with 2 389 
averages per measurement; RC2, recovery cycle part 2 with subtraction of the response to the 390 
conditioning stimulus and with 4 averages per measurement. A. The control stimulus tracked 391 
the 2-µV target with a virtually constant value of 1.3 mA for the entire recording. B. The 392 
peak-to-peak amplitudes for the unconditioned test potential (2-µV target marked by 393 
horizontal line). The variability of the CSAP is due to the intrinsic variability of the recording 394 
and the variability of the tracking stimulus. C. Superimposed responses to the unconditioned 395 
test stimulus (timing indicated by the solid bar) for the entire recording. Peak-to-peak 396 
measurements of the response were made within the interval marked by the arrows, and 397 
correspond to the values displayed in B. 398 
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  400 
Figure 5: Excitability of low-threshold cutaneous afferents. The maximal CSAP is 401 
indicated after the subject. The filled circles denote the low target threshold (2 µV) 402 
recordings, and the open circles the standard (40-50%) targets. Extended threshold 403 
electrotonus (top row). The reduction in threshold to conditioning currents of ±20% and 404 
±40% and -70% of the target threshold. Recovery cycle (middle row). The recovery of 405 
excitability following a supramaximal stimulus. Strength-duration properties (bottom 406 
row). Plotted here as charge versus stimulus width. The slope represents rheobase, and not 407 
surprisingly is steeper for the standard targets. The absolute value of the X-intercept is the 408 
strength-duration time constant, which is longer for the 2-µV targets. 409 
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  411 
Figure 6: Threshold tracking in patients with neuropathies and pathologically small 412 
maximal CSAPs. 413 
Top row: For each patient, 10 consecutive traces of the tracked 40% target potential are 414 
shown. The target potential is clearly distinguishable from the background noise. 415 
Middle row: Threshold electrotonus waveforms for each of the neuropathic conditions. The 416 
upward deflection at the start of depolarizing threshold electrotonus is probably due 417 
inadvertent activation by the conditioning stimulus. 418 
Bottom row: Recovery of excitability following activation by a supramaximal stimulus. 419 
*CIDP = chronic inflammatory demyelinating polyneuropathy  420 
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Figure 7: Repeatability of small target recordings (Subject #2). Axonal excitability 422 
recordings in the same subject on five different occasions, tracking a 10% CSAP (4.1± 0.3 423 
µV). The open circles represent the mean data and the lines the recordings from different 424 
occasions. A. Charge-duration plot (QT) of strength-duration properties. The slope of the 425 
lines is rheobase, and the X-intercept magnitude corresponds to the strength-duration time 426 
constant (SDTC). B. The recovery cycle (RC) plots the recovery of an axon following a 427 
supramaximal discharge. C. Extended threshold electrotonus (TE) recording with 428 
conditioning levels of ±20, ±40 and -70% of the unconditioned test threshold. D. Current-429 
threshold (IV) relationship plots the threshold reduction versus current strength from +50 to -430 
100% of threshold. The mean data are not displayed for the QT plot (A), because that may 431 
lead to the erroneous interpretation of the X-intercept magnitude as the mean SDTC. 432 
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Figure Legends 434 
Figure 1. Battery-powered isolated preamplifier for small sensory potentials. 435 
A. Circuit schematic. The circuit is powered by two pairs of 9-volt batteries and the subject 436 
is galvanically isolated from the data acquisition system by the isolation amplifier (ISO124P). 437 
The subject ground is tied to the midpoint (GND1) of the pair of batteries on the subject’s 438 
side of the isolation amplifier, whereas the amplifier’s output is referenced to the midpoint 439 
(GND2) of the pair of batteries on the data acquisition side of the isolation amplifier. The 440 
instrumentation amplifier (AD8221BRZ) provides the critical first stage of amplification and 441 
is set to a gain of x250 with a 1% 200Ω resistor (matched as close as possible to 198.4Ω). 442 
The first active filter chip decouples any dc-offset potentials. The second active filter is a 2-443 
pole Butterworth high-pass filter (fc=2Hz) for the removal of motion artefact. The 3rd and 444 
4th active filter chips combined provide a 4-pole low-pass Bessel filter (fc=2 kHz) to limit 445 
the measurement bandwidth. B. Normalised frequency response measured with a 0.5-mV sine 446 
wave. The gain is normalised to the maximal bandpass response. The dotted lines indicate the 447 
band-pass (2 Hz to 2 kHz). The open circles indicate the low-pass filter characteristics of two 448 
applications of a 1-2-1 Gaussian filter for data sampled at 10 kHz. C. Common mode 449 
rejection vs. frequency. The dotted line corresponds to the -3dB frequency of the low pass 450 
filter, and shows a minimal CMRR of 125 dB over the amplifier’s bandwidth. 451 
 452 
Figure 2: Recovery from stimulus artefact during CSAP recruitment. Left column. 453 
Averaged CSAP response waveforms to six consecutive stimuli (0.5-ms wide) of 454 
progressively increasing intensity for three subjects. Right column. Peak-to-peak 455 
measurements for each of the waveforms in the left column. The arrows indicate the 2-µV 456 
target for each subject. 457 
 458 
Figure 3: Signal-to-noise ratio (Subject #2 in Fig. 2). The data represents the peak-to-peak 459 
amplitudes of the control channel (unconditioned test; open circles) and the equivalent noise 460 
(closed circles). The equivalent noise was measured in an earlier window which preceded the 461 
test stimulus. The solid lines indicate the mean amplitude and the dashed lines the mean 462 
noise. The vertical bars indicate one standard deviation from the mean. A. 10% target (~4 463 
25 
 
µV) of maximal CSAP. B. Target 2 µV. Note that some of the variability in the test data 464 
(open circles) is because the stimulus was changing to track the threshold for the target 465 
CSAP. 466 
 467 
Figure 4:  Threshold tracking a 2 µV target potential (Subject #3). The various 468 
components of the recording are marked below the data in A: SD, strength-duration 469 
relationship; TE, threshold electrotonus; IV, current-threshold relationship; RC1, recovery 470 
cycle part 1 with 2 averages per measurement; RC2, recovery cycle part 2 with subtraction of 471 
the response to the conditioning stimulus and with 4 averages per measurement. A. The 472 
control stimulus tracked the 2-µV target with a virtually constant value of 1.3 mA for the 473 
entire recording. B. The peak-to-peak amplitudes for the unconditioned test potential (2-µV 474 
target marked by horizontal line). The variability of the CSAP is due to the intrinsic 475 
variability of the recording and the variability of the tracking stimulus. C. Superimposed 476 
responses to the unconditioned test stimulus (timing indicated by the solid bar) for the entire 477 
recording. Peak-to-peak measurements of the response were made within the interval marked 478 
by the arrows, and correspond to the values displayed in B. 479 
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Figure 5: Excitability of low-threshold cutaneous afferents. The maximal CSAP is 481 
indicated after the subject. The filled circles denote the low target threshold (2 µV) 482 
recordings, and the open circles the standard (40-50%) targets. Extended threshold 483 
electrotonus (top row). The reduction in threshold to conditioning currents of ±20% and 484 
±40% and -70% of the target threshold. Recovery cycle (middle row). The recovery of 485 
excitability following a supramaximal stimulus. Strength-duration properties (bottom 486 
row). Plotted here as charge versus stimulus width. The slope represents rheobase, and not 487 
surprisingly is steeper for the standard targets. The absolute value of the X-intercept is the 488 
strength-duration time constant, which is longer for the 2-µV targets. 489 
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Top row: For each patient, 10 consecutive traces of the tracked 40% target potential are 493 
shown. The target potential is clearly distinguishable from the background noise. 494 
Middle row: Threshold electrotonus waveforms for each of the neuropathic conditions. The 495 
upward deflection at the start of depolarizing threshold electrotonus is probably due 496 
inadvertent activation by the conditioning stimulus. 497 
Bottom row: Recovery of excitability following activation by a supramaximal stimulus. 498 
*Chronic Inflammatory Demyelinating Polyneuropathy 499 
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µV). The open circles represent the mean data and the lines the recordings from different 503 
occasions. A. Charge-duration plot (QT) of strength-duration properties. The slope of the 504 
lines is rheobase, and the X-intercept magnitude corresponds to the strength-duration time 505 
constant (SDTC). B. The recovery cycle (RC) plots the recovery of an axon following a 506 
supramaximal discharge. C. Extended threshold electrotonus (TE) recording with 507 
conditioning levels of ±20, ±40 and -70% of the unconditioned test threshold. D. Current-508 
threshold (IV) relationship plots the threshold reduction versus current strength from +50 to -509 
100% of threshold. The mean data are not displayed for the QT plot (A), because that may 510 
lead to the erroneous interpretation of the X-intercept magnitude as the mean SDTC. 511 
 512 
References 513 
Benatar M, Wuu J, Peng L. Reference data for commonly used sensory and motor nerve conduction 514 
studies. Muscle & nerve, 2009; 40: 772‐94. 515 
Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. 516 
Muscle & nerve, 1998; 21: 137‐58. 517 
Eduardo E, Burke D. The optimal recording electrode configuration for compound sensory action 518 
potentials. Journal of neurology, neurosurgery, and psychiatry, 1988; 51: 684‐7. 519 
Howells J, Trevillion L, Bostock H, Burke D. The voltage dependence of I(h) in human myelinated 520 
axons. The Journal of physiology, 2012; 590: 1625‐40. 521 
Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new 522 
approach in clinical testing. Muscle & nerve, 2000; 23: 399‐409. 523 
27 
 
Kiernan MC, Isbister GK, Lin CS‐Y, Burke D, Bostock H. Acute tetrodotoxin‐induced neurotoxicity after 524 
ingestion of puffer fish. Annals of neurology, 2005; 57: 339‐48. 525 
Kiernan MC, Lin CS‐Y, Andersen KV, Murray NM, Bostock H. Clinical evaluation of excitability 526 
measures in sensory nerve. Muscle & nerve, 2001; 24: 883‐92. 527 
Krarup C. Compound sensory action potential in normal and pathological human nerves. Muscle & 528 
nerve, 2004; 29: 465‐83. 529 
Krarup C, Moldovan M. Nerve conduction and excitability studies in peripheral nerve disorders. 530 
Current opinion in neurology, 2009; 22: 460‐6. 531 
Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin‐induced neurotoxicity and the 532 
development of neuropathy. Muscle & nerve, 2005; 32: 51‐60. 533 
Krishnan AV, Lin CS‐Y, Kiernan MC. Activity‐dependent excitability changes suggest Na+/K+ pump 534 
dysfunction in diabetic neuropathy. Brain : a journal of neurology, 2008; 131: 1209‐16. 535 
Krishnan AV, Lin CS‐Y, Park SB, Kiernan MC. Axonal ion channels from bench to bedside: a 536 
translational neuroscience perspective. Progress in neurobiology, 2009; 89: 288‐313. 537 
Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Kiernan MC. Sensory nerve excitability and 538 
neuropathy in end stage kidney disease. Journal of neurology, neurosurgery, and psychiatry, 2006; 539 
77: 548‐51. 540 
Kuwabara S, Misawa S. Pharmacologic intervention in axonal excitability: in vivo assessment of nodal 541 
persistent sodium currents in human neuropathies. Current molecular pharmacology, 2008; 1: 61‐7. 542 
Marchand P, Marmet L. Binomial smoothing filter: A way to avoid some pitfalls of least squares 543 
polynomial smoothing. Review of scientific instruments, 1983; 54: 1034‐41. 544 
Nodera H, Rutkove SB. Changes of the peripheral nerve excitability in vivo induced by the persistent 545 
Na+ current blocker ranolazine. Neuroscience letters, 2012; 518: 36‐40. 546 
Park SB, Lin CS‐Y, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Dose effects of oxaliplatin 547 
on persistent and transient Na+ conductances and the development of neurotoxicity. PloS one, 548 
2011; 6: e18469. 549 
Park SB, Lin CS‐Y, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin‐induced 550 
neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain : a journal of 551 
neurology, 2009; 132: 2712‐23. 552 
Shibuta Y, Nodera H, Mori A, Okita T, Kaji R. Peripheral nerve excitability measures at different target 553 
levels: the effects of aging and diabetic neuropathy. Journal of clinical neurophysiology : official 554 
publication of the American Electroencephalographic Society, 2010; 27: 350‐7. 555 
Tomlinson S, Burke D, Hanna M, Koltzenburg M, Bostock H. In vivo assessment of HCN channel 556 
current (I(h)) in human motor axons. Muscle & nerve, 2010; 41: 247‐56. 557 
Trevillion L, Howells J, Bostock H, Burke D. Properties of low‐threshold motor axons in the human 558 
median nerve. The Journal of physiology, 2010; 588: 2503‐15. 559 
Wagenaar DA, Potter SM. Real‐time multi‐channel stimulus artifact suppression by local curve 560 
fitting. Journal of neuroscience methods, 2002; 120: 113‐20. 561 
 562 
